Sacituzumab-govitecan in metastatic triple-negative breast cancer: a multicenter effectiveness and safety study

Area of Science:

• Oncology
• Pharmacology
• Clinical Trials

Background:

• Sacituzumab-govitecan (Sgov) is an antibody-drug conjugate approved for metastatic triple-negative breast cancer (mTNBC).
• Limited real-world data exists for Sgov in mTNBC patients.
• The pivotal ASCENT trial provides a benchmark for Sgov efficacy and safety.

Purpose of the Study:

• To evaluate the real-world effectiveness and safety of Sgov in mTNBC patients.
• To compare Sgov outcomes in a real-world setting with the ASCENT trial results.
• To identify patient subgroups that may benefit less from Sgov treatment.

Main Methods:

• Retrospective analysis of 46 mTNBC patients treated with Sgov across three major hospitals.
• Data collection included patient demographics, Eastern Cooperative Oncology Group (ECOG) performance status, and treatment outcomes.
• Comparison of real-world data with findings from the ASCENT trial.

Main Results:

• Real-world effectiveness of Sgov appeared slightly lower than anticipated from clinical trials.
• Patients with an ECOG performance status of two or higher demonstrated significantly reduced benefit from Sgov.
• The safety profile of Sgov was deemed acceptable in this patient cohort.

Conclusions:

• Sgov demonstrates an acceptable safety profile in real-world mTNBC treatment.
• Real-world effectiveness may not fully align with pivotal trial data, particularly for patients with compromised performance status.
• Further investigation into patient selection and treatment optimization for Sgov in mTNBC is warranted.